Aptus Pharma Ltd has notified the BSE Ltd of a Board of Directors meeting scheduled for Saturday, August 8, 2026, at 4:00 p.m. The meeting will be held at the company's Head Office located at RK Trade Tower, Wing A, Office 616 to 619, Near Sheetal Park Circle, 150 Feet Ring Road, Rajkot, Gujarat, India – 360006. The intimation was issued pursuant to Regulation 29(1)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Preferential Allotment on the Agenda

The primary agenda of the upcoming board meeting centres on evaluating a proposal to raise funds through the capital markets. The board will consider and deliberate upon the following key item:

The proposal is subject to such approvals, permissions, and sanctions of the shareholders of the company and/or regulatory and statutory authorities as may be required.

Trading Window Closure

In accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons and their Immediate Relatives, Aptus Pharma has announced the closure of its trading window. Key details of the trading window closure are as follows:

• Effective from: August 5, 2026, at 6:00 p.m.
• Applicable to: All Designated Persons and their Immediate Relatives
• Closure period: Until the expiry of 48 hours after the outcome of the board meeting is disseminated to the stock exchanges under Regulation 30 of the SEBI LODR Regulations
• All Designated Persons and their Immediate Relatives have been directed not to trade in the securities of the company during the aforesaid closure period.

Company Details

The intimation was signed by Tejash Hathi, Managing Director (DIN: 03151221) of Aptus Pharma Ltd on August 5, 2026. The company's registered address is Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi, Ahmedabad, Gujarat – 382427, India, and it can be reached at aptuspharma@rediffmail.com or through its website at www.aptus-pharma.com .

Aptus Pharma Limited's board has approved a proposal to raise funds aggregating up to ₹51 crore for the expansion of its business operations. The decision was taken during a board meeting held on June 12, 2026, at the corporate office in Rajkot, Gujarat. The fund-raising mix includes preferential allotment of securities up to ₹35 crore, debt finance or borrowings up to ₹10 crore, and internal accruals of ₹6 crore.

The preferential allotment will be undertaken in accordance with the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The board has authorized and delegated authority to Managing Director Tejas Hathi to identify, evaluate, and negotiate with prospective investors. He is also tasked with conducting due diligence and finalizing the details of proposed allottees for placing the matter before the board for final approval.

The board clarified that the resolutions passed are enabling in nature, establishing the maximum ceiling for fund raising. Specific details, including the issue price, number of securities, identity of allottees, and the record date, have not been finalized yet. These material particulars will be deliberated upon and approved at a subsequent board meeting.

The implementation of the preferential allotment is subject to necessary approvals, including a special resolution from shareholders. The company will make a comprehensive disclosure to the stock exchanges in accordance with SEBI LODR Regulations once the board finalizes the specific terms at a later stage.